The hosts of Morning Brew Daily made a simple argument on a recent episode that the idea of the “Ozempic economy” should be ...

Eli Lilly is coming off an impressive first-quarter performance, with sales soaring by 56%.

Learn more Eli Lilly raised its full-year 2026 revenue guidance to between $82 billion and $85 billion after first-quarter ...

Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.

Surging consumer demand for blockbuster weight-loss drugs helped offset their declining prices.

After accounting for 14% of all prescription drug spending in 2025, the blockbuster GLP-1 drug class is on track to continue rapid growth and alter pharmaceutical spending trends.  For example, Eli ...

Eli Lilly (NYSE: LLY) continues to prove the doubters wrong. Despite fears that the company's shares are overvalued, and that ...

Eli Lilly alleged that Empower lured customers away from their brand-name GLP-1 products and toward the pharmacy's ...

Public health plans should cover the blockbuster drug Mounjaro for patients with Type 2 diabetes, Canada’s Drug Agency says, as long as manufacturer Eli Lilly Split N/A N/A 08/29/22 N/A 08/29/22 N/A 1 ...

A federal judge ruled Eli Lilly & Co. can proceed with its lawsuit against a business selling copycat versions of its obesity ...

Eli Lilly's weight loss pill launch has been closely watched after the successful start of Novo Nordisk's Wegovy pill.

Eli Lilly (LLY) stock dropped 3% on Foundayo liver concerns. Analysts say the decline is overdone and recommend buying the ...